Biofrontera Inc. (BFRI)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$6.5M
Cash & Equivalents
$0.1M
Quarterly Burn Rate
279 mo
Est. Cash Runway
$14M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
AMINOLEVULINIC ACID HYDROCHLORIDE
AMELUZ |
APPROVED | Acne Vulgaris, Actinic Keratoses, Actinic Keratosis, Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma, Keratosis, Keratosis, Actinic, Photodamage, Skin Neoplasms, Superficial Basal Cell Carcinoma |
|
BENZOYL PEROXIDE, ERYTHROMYCIN
AKTIPAK |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Bas... | PHASE3 | Active Not Recruiting | 187 |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | PHASE2 | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.